0.605
0.02 (4.13%)
| Penutupan Terdahulu | 0.581 |
| Buka | 0.648 |
| Jumlah Dagangan | 54,433 |
| Purata Dagangan (3B) | 213,446 |
| Modal Pasaran | 3,678,956 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.43 |
| Harga / Jualan (P/S) | 6.96 |
| Harga / Buku (P/B) | 0.900 |
| Julat 52 Minggu |
| Margin Keuntungan | -102.80% |
| Margin Operasi (TTM) | -69.57% |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 382.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 914.75% |
| Nisbah Semasa (MRQ) | 0.540 |
| Aliran Tunai Operasi (OCF TTM) | -9.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.39 M |
| Pulangan Atas Aset (ROA TTM) | -37.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,708.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Redhill Biopharma Ltd. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.71 |
|
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Institusi | 4.30% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |